quinta-feira, fevereiro 10, 2005
Carta do EATG sobre tipranavir em Portugal
February 10, 2005.
Boehringer Ingelheim
Germany
Dear Thomas Fischer,
During the meeting of the European Community Advisory Board (ECAB) and Boehringer Ingelheim at Brussels on 29 January 2005 we brought to your attention problems with the expanded access programme (EAP) for Tipranavir in Portugal. Unfortunately, these problems have not been solved until today.
Results of Resist-1 and 2 trials which Doug Mayers presented at Brussels suggest that Tipranavir can be a valuable treatment option for people with HIV who have failed other regimens. In a press release by Boehringer Ingelheim dated 25 October 2004, Paul Fonteyne, Executive Vice President and Head of Sales & Marketing at Boehringer Ingelheim Pharmaceuticals, Inc. is quoted with the words that "Boehringer Ingelheim has worked diligently to develop tipranavir as quickly as possible in response to the urgent need for new therapies for treatment-experienced HIV-positive patients."
In Portugal, an estimated 200-300 persons with HIV are in urgent need for Tipranavir. Due to the problems with the EUP / EAP programmes for Boehringer's Tipranavir, only 2 patients in Portugal are included in the Tipranavir EAP now and none in the EUP. We urgently ask you to take immediate action for a solution of the access problem and to respond to the urgent need for Tipranavir now. Access to Tipranavir must be assured immediately in Portugal for those who need it most.
Kind regards,
Stephan Dressler
ECAB-liaison to Boehringer Ingelheim
Boehringer Ingelheim
Germany
Dear Thomas Fischer,
During the meeting of the European Community Advisory Board (ECAB) and Boehringer Ingelheim at Brussels on 29 January 2005 we brought to your attention problems with the expanded access programme (EAP) for Tipranavir in Portugal. Unfortunately, these problems have not been solved until today.
Results of Resist-1 and 2 trials which Doug Mayers presented at Brussels suggest that Tipranavir can be a valuable treatment option for people with HIV who have failed other regimens. In a press release by Boehringer Ingelheim dated 25 October 2004, Paul Fonteyne, Executive Vice President and Head of Sales & Marketing at Boehringer Ingelheim Pharmaceuticals, Inc. is quoted with the words that "Boehringer Ingelheim has worked diligently to develop tipranavir as quickly as possible in response to the urgent need for new therapies for treatment-experienced HIV-positive patients."
In Portugal, an estimated 200-300 persons with HIV are in urgent need for Tipranavir. Due to the problems with the EUP / EAP programmes for Boehringer's Tipranavir, only 2 patients in Portugal are included in the Tipranavir EAP now and none in the EUP. We urgently ask you to take immediate action for a solution of the access problem and to respond to the urgent need for Tipranavir now. Access to Tipranavir must be assured immediately in Portugal for those who need it most.
Kind regards,
Stephan Dressler
ECAB-liaison to Boehringer Ingelheim
